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Glyco-engineeringMonoclonal antibody and Fc fusion protein drugs are complex heterogeneous mixtures of numerous
different protein variants and modifications. N-glycosylation as one of the most complex post-
translational modification influences the structural characteristics of the antibodies Fc part thereby
potentially modulating effector function and pharmacokinetics. Several investigations on the relationship
between N-glycosylation and pharmacokinetics have been published. However, this structure–function
relationship is not fully understood. In this review potential alterations with focus on N-glycosylation
of mAbs and Fc fusion proteins and the possible effects on the pharmacokinetics are reviewed and the
current understandings of the underlying mechanisms are described.
 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The fusion of murine myeloma cells with B-cells was a ground-
breaking experiment of Köhler and Milstein and made production
of antibodies in cell culture possible [1]. It was the beginning of
immunoassays and therapeutic antibodies. In 2012, more than
35 years later, 34 recombinant monoclonal antibodies (mAbs)
were marketed in the EU and US, mostly produced in CHO and
SP2/0 cells [2]. The vast majority of marketed mAbs belongs to
the IgG class or more precisely to the subclasses IgG1 and to some
extent IgG2 and IgG4. Two-thirds of the marketed mAbs are either
human or humanized and a small percentage is chimeric or murine
[2]. With more than 1300 amino acids resulting in a mass of
approximately 150 kDa mAbs are large molecules built from two
heavy chains with 50 kDa each and two light chains with 25 kDa
each (Fig. 1). The different heavy chains (c1, c2, c3 and c4) divide
the IgGs into their subclasses 1–4. The light chains are the j-type
and k-type. Heavy and light chains are connected by disulfide
bridges giving the antibody its Y-shaped structure (Fig. 1). Intra-
chain disulfide bridges further stabilize the folding, 16 disulfide
bridges per IgG1 and 7 per chain. The heavy and light chains con-
sist of different domains. The variable domains variable light (VL)and variable heavy (VH) contain hypervariable regions that are
responsible for antigen binding. The remaining domains are con-
served sequences named constant domains constant light (CL)
and constant heavy (CH1–3). The CH2 domain of each heavy chain
contains one N-glycosylation site at approximately Asn297 and
about one-fifth of human IgGs carry a N-glycosylation motif in
the variable region [3,4]. The size and structure of IgGs give rise
to a large number of possible alterations and modifications
(Table 1) turning IgG drugs and in conclusion recombinant mAb
drugs to heterogenic protein mixtures. Several of these alterations
can have tremendous influence on the structure, PK and function of
monoclonal antibodies. The complex post-translational modifica-
tion of antibodies, N-glycosylation, will be discussed in detail in
the following.2. N-glycosylation and its influence on mAb structure and mAb
effector function
Like most extracellular glycoproteins, therapeutic proteins and
specifically also mAbs undergo glycosylation in the ER and Golgi
network of cells. The glycan structures of therapeutic mAbs can
be of importance for the efficacy and safety of the drug [21]. Mon-
oclonal antibodies have one conserved N-linked glycosylation at
the Fc part at position N297. Approximately 20% contain a second
N-linked glycosylation site in their variable region. Both sites are
Fig. 1. Schematic structure of an IgG1 molecule. An IgG consists of two heavy and two light chains that contain several domains. The variable domains variable light (VL) and
variable heavy (VH) that form the antigen binding site and the constant domains CL (constant light) and CH1–3 (constant heavy) building the framework. The IgG can be
furthermore divided into the Fab (fragment antigen binding) and Fc (fragment crystallizable) which induce the effector functions. On the right possible modifications and
alterations of the IgG are listed.
Table 1
Common modifications of biopharmaceuticals and their impact on structure and function.
Modification Effect Reference(s)
Glu or Gln cyclization at N-terminus Loss of positive N-terminal charge [5–7]
Lys variants at C-terminus Introduction of a positive charge [7,8]
Deamidation (Asn to Asp) Introduction of a negative charge (Asn to Asp) [5,7,9–11]
Isomerization (Asp to isoAsp) Introduction of an additional CH2 group into the protein backbone (Asp to
iAsp)
[5,7,12]
Deamidation (Gln to Glu) Introduction of a negative charge [13,14]
Glycation Loss of a positive charge [7,15,16]
Oxidation (Cys, His, Met, Tyr, Trp) Increase of polarity [5,7]
Disulfide bond heterogeneity (Shuffling, thioether and trisulfide
formation)
Changes in the protein conformation [17–20]
Glycosylation (N-linked, O-linked) Influence on the structure and function See next
section
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cals shows a high grade of heterogeneity and N-glycans belong
to the most complex and diverse structures in nature due to the
high number of different sugar moieties and the multitude of
possible linkages. Fig. 2 shows the three different N-glycan types
high mannose, complex and hybrid that are found on IgGs with
their respective linkage. Complex and hybrid types exist with core
fucosylation, addition of a fucose residue to the innermost
N-acetylglucosamine, and without core fucosylation. mAbs repre-
sent a special group of glycoproteins as their N-glycans are of
limited size. mAbs are usually free of N-glycans with more than
two antennae and furthermore the sialic acid content is low com-
pared with other glycoproteins [22]. This circumstance can be
explained by the fact that the glycosylation site in the CH2 domain
at Asn297 is buried in the protein structure. Typically, antibodies
contain a high percentage of complex bi-antennary glycans with
core-fucosylation [22–24].
N-glycans have important structural functions. They stabilize
the CH2 domain of IgGs and deglycosylation makes mAbs ther-
mally less stable and more susceptible to unfolding. In addition
deglycosylated mAbs are more prone to aggregation [25]. Not only
thermal and colloidal stability, but also functionality of the IgG is
influenced by the attached N-glycans and their size [26]. In
addition to the stabilization of the CH2 domain the attached
N-glycans greatly influence the folding of the Fc part. Krapp et al.
investigated crystalized Fc parts of IgG molecules with different
homogenous glycosylations and could demonstrate that theconformation of the CH2 domain depends on the attached N-
glycans [27]. Larger N-glycans, e.g. bi-antennary complex type
with terminal galactosylation, open up the Fc part in the CH2
region to a horseshoe like structure, whereas smaller attached N-
glycans like the core structure favor a more ‘‘closed” Fc conforma-
tion. This open and closed formation can greatly influence the
effector functions induced by interactions of the Fc part with Fc
receptor molecules. The fact that crystallization of deglycosylated
IgG was not possible due to the high flexibility of the CH2 domain
shows the importance of N-glycan protein interactions [27].
Hydrogen/Deuterium exchange MS experiments resulted in similar
findings. Houde et al. showed that terminal galactosylation has
major impact on the conformation of the Fc part and that fucosyla-
tion alone does not impact the conformation [28]. NMR analysis of
G2F glycosylated mAbs revealed that the terminal galactose
residues are exposed and accessible for protein binding and that
there are differences between the 1,3 and the 1,6 arm concerning
flexibility and accessibility [29]. These findings led to the assump-
tion that Fc N-glycosylation influences the effector function of
proteins interacting with the CH2 domain. Upon antigen binding
mAbs are able to induce effector functions mediated by their
Fc-part. By binding to Fc-receptors or complement proteins mAbs
induce antibody-dependent cell-mediated cytotoxicity (ADCC) or
complement-dependent cytotoxicity (CDC), respectively. ADCC
is induced after binding of Fc-c receptors (FccR) to the Fc part
[30]. The affinity of FccRs to the Fc part is influenced by
N-glycosylation in the CH2 domain [28,31–34]. As a consequence
Fig. 2. Types of N-glycans. The three different types (High Mannose, Complex and Hybrid) share a common core structure including the first two N-acetylglucosamine
residues and the first three mannose residues.
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ing affinity of the complement protein C1q to the IgG Fc which
is involved in CDC is also influenced by N-glycosylation and
an increasing content of terminal galactose enhances CDC [35].
By influencing CDC and ADCC, two important effector functions
of therapeutic mAbs, N-glycosylation was thought to also have
an impact on the pharmacokinetics of the glycosylated
biopharmaceuticals.3. N-glycosylation and its effect on pharmacokinetics of mAbs
Monoclonal antibodies are large and complex structures with a
different behavior in terms of their pharmacology and pharmacoki-
netics (PK) compared to low molecular weight drugs. Monoclonal
antibodies show dose-dependent maximal plasma concentrations
in the range of lg/ml (nM range). mAbs typically exhibit a body
half-life between 10 and 25 days, since they are not eliminated
through kidney filtration due to their size and additionally escape
fast degradation in the lysosomes through the neonatal Fc receptor
(FcRn) recycling mechanism [36,37]. mAbs are usually adminis-
tered parenterally by subcutaneous (sc), intramuscular (im) or
intravenous (iv) injection. Whereas iv bioavailability is 100% per
definition, for sc and im administration bioavailability values of
50–100% are mostly reported [36].
Already in the 1970s, first evidence for the influence of sialic
acids on the pharmacokinetics of glycoproteins was reported. Mor-
ell et al. observed that desialylated plasma proteins were cleared
faster from circulation after injection into rats [38]. There are
two known major pathways for selective glycoprotein clearance.
Glycoproteins in circulation with accessible terminal galactosyla-
tion are bound and cleared by the asialoglycoprotein receptor
expressed in the liver [39,40]. The second way of selective
clearance of glycoproteins is executed by the mannose receptor
which is most markedly expressed on immune cells [41–43].
The mannose receptor binds selectively to mannose and N-
acetylglucosamine residues of N-glycans [41,42]. The enzymatic
conversion of glycans in vivo is the third option explaining the
selective removal of distinct glycoforms [44–46]. There are two
basic options to investigate the effect of different glyco-variants
on protein pharmacokinetics. Either distinct glyco-variants are
enriched and compared in several study groups or the relative
composition of different glyco-variants is directly followed in one
study group. Millward et al. studied a mAb enriched to a high man-
nose portion at the Fc part of approximately 50% and a second mAb
enriched for glycosylation in the Fab region. The PK profiles of the
different mAb preparations were compared in mice by ELISA andthe glycan pattern was analyzed at several time points by HPLC.
No significant differences in PK properties were found [47]. A sec-
ond investigation in mice which compared PK parameters of
degalactosylated IgGs with non-modified IgG came to the conclu-
sion that degalactosylated IgG with terminal GlcNAc has a signifi-
cantly longer half-life [48]. Production and characterization of
three differently glycosylated mAb qualities (Hybrid (+/ F), Com-
plex (+/ F) and high mannose) against CD20 with bioassays (CDC,
ADCC) and an in vivo study in mice demonstrated that the complex
glycosylated mAb had a longer half-life, which is independent from
fucosylation. Hybrid glycosylated mAb had a slightly shorter half-
life and high mannose glycosylated mAb showed a strong decrease
in half-life [49]. On summarizing, the results from mice glycan PK
profiling render an unclear picture with two studies reaching con-
tradictory conclusions concerning the influence of high mannose
structures on mAb PK in mice [47,49].
Analysis of affinity purified mAb (IgG2) from clinical samples of
two healthy human test subjects showed that the relative contri-
bution of high mannose species M6–M9 to the total mAb plasma
concentration decreased over time whereas M5 levels increased
by about the same percentage. It was hypothesized that the reduc-
tion of the IgG2 high mannose glycan blood levels is due to glycosi-
dase activity in serum converting M6–M9 into M5 and not due to
faster clearance. This hypothesis was supported with results from
an in vitro assay. Incubation of the IgG2 in serum led to the same
high mannose conversion as observed in the case study [44]. The
same group later published a second glycan PK profiling by mass
spectrometry approach based on glycopeptide analysis by MS
[45]. Analysis of samples from four human subjects after adminis-
tration of either one IgG1 or one of three IgG2 molecules resulted
in the finding that high mannose N-glycan M5 is selectively cleared
from serum [45]. The authors furthermore showed that the IgG2
M5:M5 glycoform, the pairing of two M5 glycosylated heavy
chains during protein biosynthesis is favored. A similar investiga-
tion of an IgG1 biopharmaceutical in humans confirmed the previ-
ously published [44] conversion of high mannose glycans in vitro.
The results of a clinical study including 15 healthy volunteers pub-
lished in combination with the in vitro study showed that M5 had
an increased serum clearance whereas M6 andM7 decreased in the
first 6 h after administration followed by decreasing M5 levels and
constant M6 and M7 portions (Fig. 3) [46]. We have recently
reported that this high mannose conversion and selective clear-
ance of M5 are similar in rabbits after subcutaneous administration
of an IgG1 [50]. The production of mAbs with one distinct N-glycan
and administration to mice demonstrated that a mAb with only M5
or M8/9 has an increased clearance and a shorter half-life. Further-
more, it was highlighted that the glycan pattern of the mAb with
Fig. 3. Mean percentage of glycan species of mAb-1 in serum following single dose administration in healthy individuals. From Alessandri et al. mAbs 2012, 4, 509–520 [46].
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tion could be reproduced in vitro by incubation of the mAb in mice
serum [51]. Conversion of high mannose glycans to M6 instead of
M5 reported for mice implies a different underlying mechanism. A
mouse study comparing yeast N-glycosylation (yeast specific high
mannose type) and human glycosylation (complex type) revealed
that antibodies carrying yeast glycosylation have shorter serum
half-life than antibodies with human glycosylation [52]. The influ-
ence of the glycosylation of the variable domain on antibody clear-
ance was investigated by different groups [47,53]. As already
mentioned Millward et al. did not find any influence of the variable
domain N-glycosylation on the PK. In contrast Huang et al. came to
the conclusion that molecules with bi-antennary glycans lacking
galactosylation (terminal GlcNAc) attached in the variable domain
are cleared slightly faster from circulation [53].
4. N-glycosylation and its effect on pharmacokinetics of Fc
fusion proteins
Fc part containing fusion proteins are closely related to mAbs,
because of the effector function induced by the Fc part of both bio-
pharmaceuticals. Fc fusion proteins often carry several N-
glycosylation sites in the non-IgG fusion protein part [54–56].
There are a few reports on an influence of the terminal glycan resi-
dues of Fc fusion proteins on PK. Keck et al. compared Fc fusion
protein batches with different N-glycosylation pattern, specifically
terminal GlcNAc, galactosylation and sialylation [56]. However, no
site specific N-glycan analysis was performed which would enable
to link effects to the Fc or the fusion protein part. The authors
found that terminal GlcNAc was cleared faster. It was hypothesized
that the mannose receptor might be responsible for the clearance
as the 3D structure of the receptors demonstrated that the receptor
can bind terminal GlcNAc containing glycans [56]. In accordance
with these findings Jones et al. represented that N-glycans with
terminal GlcNAc residues have a higher clearance rate. Their pro-
tein of interest was the fusion protein lenercept containing a Fc
part and two extracellular domains of a TNF-alpha receptor. Sialic
acids and terminal galactosylation revealed only minor to no
impact on the PK [55]. Kogelberg et al. postulated a clearance
mechanism for highly mannosylated proteins after studying an
antibody Fc–enzyme fusion protein produced in the yeast Pichiapastoris. They provided evidence for clearance of the glycoprotein
by the mannose receptor, a glycan specific receptor which is
expressed beside others in sinusoidal endothelial cells in the liver
[57]. Reports from Liu et al. comparing differently glycosylated
fusion proteins and mAbs produced in either glyco-engineered
P. pastoris or CHO cells highlighted that the sialic acid content of
fusion proteins modulates the pharmacokinetics [52,58]. Lower
levels of sialic acids correlated with decreased serum half-life.5. Analysis of N-glycosylation in pharmacokinetic studies
Immunoassays became the reference technique for PK-studies
of therapeutic proteins, especially ELISA where the protein is cap-
tured by a specific antibody or in the case of therapeutic antibodies
also by an anti-idiotypic antibody, an anti-species antibody or the
appropriate antigen and finally detected by an enzyme-linked sec-
ondary antibody [59]. However structural changes such as deami-
dation, oxidation and especially the heterogeneity of glycoforms of
the therapeutic protein, as discussed in previous sections, could
alter the pharmacokinetic properties [60,61] and immunoassay
techniques are not able to detect such types of differences
[59,62]. ELISA simultaneously quantifies all protein variants deliv-
ering the average PK profile of all variants and cannot distinguish
between glyco-variants. Hence different analytical techniques are
necessary. For the investigation of individual N-glycans LC and
MS based approaches were mostly used in the literature
[44–47,49,53–55]. Beside the analysis of intact glycoproteins
which provides information about the most abundant glycoforms,
the analysis of glycopeptides and released N-glycans is frequently
used. Enzymatic release of N-glycans following labeling with a flu-
orophore like anthranilamide or anthranilic acid and analysis by LC
or LC-MS is perhaps the most widespread approach used in indus-
try and academia [23,24,63–69]. More sensitive approaches such
as nano-LC-MS, CE and CE-MS with LIF detection are also common
and suitable for glycan related PK investigations [70–77]. The
advantage of these technologies for the glycan PK profiling is the
possibility to analyze each N-glycan individually from a complex
mixture which in turn leads to more accurate results compared
to e.g. studies employing immunoassays after enrichment of speci-
fic glycoforms.
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As summarized in the previous sections there is strong evidence
in the literature for the influence of N-glycosylation on structure,
function and pharmacokinetics of monoclonal antibodies and Fc
fusion proteins. Consequently, glyco-engineering, the controlled
biosynthesis of only distinct glycan structures became of high
interest in the biopharmaceutical industry. There are multiple
strategies to produce biotechnology products with defined N-
linked glycans [21,78]. One straightforward yet highly sophisti-
cated approach to control the N-glycosylation of recombinant anti-
bodies is based on special in-process controls [79]. Here no
manipulation of the genome or set of enzymes is required; instead
a tight control of temperature, pH and feed is used to influence the
glycan species (e.g. high mannose and terminal galactosylation
levels). Another option to influence the glycan pattern is the use
of specific inhibitors of glycosyltransferases. Rillahan et al. demon-
strated that the addition of fluorinated monosaccharide analogs
efficiently inhibited the corresponding fucosyl or sialyltransferases
[80]. Another group used RNAi constructs to knock down a-1,3-
fucosyltransferase and b-1,2-xylosyltransferase which allowed
expression of a mAb with human N-glycans in the aquatic plant
Lemna minor. The produced mAb had a homogeneous glycan pat-
tern and better ADCC and effector function [81]. Humanization of
N-glycans in the yeast P. pastoris was also reported. By introducing
a set of human enzymes to the yeast genome it was possible to
express biopharmaceuticals with complex N-glycans instead of
the yeast high mannose glycans [82]. The reduction of the fucosy-
lation levels has been of central interest since the absence of this
single monosaccharide causes a drastic increase in efficacy. For a
permanent absence of fucose the generation of knockout cell lines
is required which can be achieved by either silencing or removing
the Fucosyltransferase 8 (FUT8) or a GDP-mannose 4,6-
dehydratase (GMD) gene [83,84]. Another approach to lower the
fucosylation is the GlycArt technology, which renders afucosylated
antibodies with a high content of bisecting glycans by overexpres-
sion of a distinct glycosyltransferase and change of the localization
domain [85]. It was shown that only the absence of the core fucose
was responsible for the enhanced ADCC, but not the presence of
the bisecting N-glycans [86]. This technology was utilized to gen-
erate two antibodies with high ADCC in the oncology area,
GA101 (obinutuzumab; approved) targeting CD20 and GA201 tar-
geting EGFR [87,88]. Another approved antibody with improved
ADCC is mogamulizumab also based on a afucosylation technology
[89].7. Conclusion and future perspectives
Monoclonal antibody drugs are complex and heterogeneous
mixtures of protein variants. The N-glycosylation on the antibody
structure can influence stability, function and pharmacokinetics.
In some publications distinct glycosylation fractions were enriched
and studied. However, with this approach a new artificial glycosy-
lation pattern is generated that does not necessarily reflect the nor-
mal N-glycosylation of the biologic of interest and may render
different outcome especially if other protein variants with an influ-
ence were co-enriched. The benefit of this approach is that simple
standard analytics e.g. utilizing immunoassays can be performed to
characterize the PK. Individual N-glycans analysis by MS based
approaches can be used to analyze the heterogeneous biopharma-
ceutical directly. The major advantage of this MS approach is that
the N-glycan levels can be analyzed in a relative manner. Individ-
ual N-glycans with influence on the PK can be identified rather
simply. However, the MS approach requires high sensitivity. The
studies investigating the relationship between N-glycosylationand pharmacokinetics led to in part contradictory findings. Overall
it is conclusive that high mannose glycans influence the PK of IgGs
by increasing the clearance rate through the mannose receptor. For
other N-glycans and glycoforms the results are less clear. Two
studies investigating IgG variable domain glycosylation rendered
inconsistent results and another study comparing differently gly-
cosylated enriched fractions reported no difference. These incon-
sistent findings may be due to differences in study set-up (e.g.
enrichment of distinct glycoforms vs. simultaneous quantification
using LC-MS based methods), species (mouse, human), IgG sub-
class and IgG source (human, humanized, etc.). Results for the
more complex glycosylated Fc fusion proteins with additional gly-
cosylation sites in the fusion protein part also show an unclear pic-
ture for the effect of N-glycosylation on the pharmacokinetics. The
N-glycans of the fusion proteins were mostly analyzed without site
specificity. The N-glycans at the Fc part are buried between the
heavy chains whereas the receptor part N-glycans could be more
accessible for the interaction with specific enzymes or receptors.
This phenomenon could result in different impact on the pharma-
cokinetics. Thus, over the last decade several investigations on the
relationship between N-glycosylation of therapeutic proteins and
pharmacokinetics were performed. With the use of sensitive tech-
nologies such as LC-MS it became possible to change the analysis
from comparing fractions of biopharmaceuticals enriched for
specific N-glycans to the direct analysis of the complex glycosy-
lated biopharmaceutical of interest. This resulted in more repro-
ducible findings. The development of glyco-engineering
technologies enabled the successful production and approval of
more homogeneously glycosylated antibodies. Especially for oncol-
ogy products the removal of the core fucose and the resulting
higher ADCC was a success. However, this complete removal of
fucose cannot always be used, as e.g. in anti-inflammatory diseases
ADCC is not a desired effector function. Here, complete fucosyla-
tion is favorable. In addition, the production process itself has a
considerable influence on the resulting N-glycan pattern. Glyco-
engineering of multiple glycosylated fusion proteins can be even
more difficult if a certain glycan is for example involved in target
binding. With the rising number of new formats of biopharmaceu-
ticals and biosimilars in development the need for N-glycan PK
profiling and comparative studies will rise as well as the need for
further glyco-engineering and optimization.Disclosures
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